Aldeyra Therapeutics (ALDX) Tops Q3 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/6/2026
- Broadcom secures role as key Apple supplier with chip deal through 2031
- Dara Khosrowshahi steps down from Grab Holdings board
- Mahindra & Mahindra Ltd (MM:IN) (MAHMF) PT Raised to INR320 at HSBC
- HSBC Downgrades Shriram Finance Ltd (SHFL:IN) to Hold
- Lockheed Martin to acquire Ultra Maritime for $3.45 billion
Aldeyra Therapeutics Announces Third-Quarter 2020 Financial Results and Provides Corporate Update
November 5, 2020 7:00 AM ESTInitiation of Phase 3 Objective Sign Trial in Dry Eye Disease Planned for the Fourth Quarter 2020
Phase 2 Clinical Trials of ADX-629 in COVID-19, Atopic Asthma, and Psoriasis Expected to Initiate in the Fourth Quarter of 2020
Top-line Results from the Phase 3 INVIGORATE Clinical Trial in Allergic Conjunctivitis Expected in the First Half of 2021
Cash, Cash Equivalents, and Marketable Securities of $86.2 Million as of September 30, 2020, Expected to Support Operations Through 2022
Management to Host Conference Call at 8:00 a.m. ET Today
LEXINGTON, Mass.--(BUSINESS... More
